Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$48.10

-0.82 (-1.68%)

, CELG

Bought by BMY

$88.34

-1.28 (-1.43%)

07:01
03/25/19
03/25
07:01
03/25/19
07:01

Bristiol-Myers highlights strategic rationale of Celgene deal in letter

Bristol-Myers Squibb Company's (BMY) Board of Directors sent an open letter to the company's shareholders regarding the previously announced definitive merger agreement with Celgene (CELG). In addition to its March 19 investor presentation, the company also made available on Bristol-Myers Squibb's website and will file with the SEC an investor presentation providing an overview of Bristol-Myers Squibb's ability to derive value from Celgene's pipeline and a Fact Sheet providing additional detail on key benefits of the transaction. The company says, "Having reviewed a full range of opportunities, from small collaborations to transformational combinations, we identified Celgene as by far the most compelling opportunity for Bristol-Myers Squibb and its shareholders, given its strategic fit in therapeutic areas we know well, attractive value, and its unique late-stage candidates and diversified but complementary Phase 1 and 2 pipeline. The timing of the transaction was also favorable both in the near-term, as we were able to secure a very favorable price, and for the long-term, as Bristol-Myers Squibb will be strengthened and diversified (focused within our chosen therapeutic areas of oncology and immunology) in an increasingly competitive environment... Before embarking on this important transaction, the Board of Directors thoroughly evaluated the acquisition against other alternatives for value creation. The nature of patent cycles in our industry means that companies like ours need to constantly rejuvenate themselves to stay ahead. Bristol-Myers Squibb has done this successfully over the past decade, and now we are focused on executing a program to supplement and eventually replace Opdivo and Eliquis - and sustaining our leadership for the future. We don't agree with recent suggestions to aggressively cut R&D and pursue leveraged share repurchases. Given that we operate in an industry that thrives on innovation, this approach is inconsistent with the creation of both sustainable revenue growth and long-term shareholder value. Similarly, in today's competitive and often overpriced environment for business development, we determined that pursuing a 'string-of-pearls' approach to pipeline development would not deliver value or pipeline opportunities that are as compelling as acquiring Celgene."

BMY

Bristol-Myers

$48.10

-0.82 (-1.68%)

CELG

Bought by BMY

$88.34

-1.28 (-1.43%)

  • 25

    Mar

  • 12

    Apr

  • 12

    Apr

  • 25

    Apr

  • 18

    May

  • 20

    May

  • 27

    Jun

  • 03

    Sep

BMY Bristol-Myers
$48.10

-0.82 (-1.68%)

02/28/19
WBLR
02/28/19
NO CHANGE
WBLR
William Blair believes Celgene takeover will ultimately close
William Blair analyst Andy Hsieh says that despite recent negative news flow, he believes Celgene's (CELG) takeover by Bristol-Myers (BMY) will ultimately close by the end of Q3. Despite the headline risk that could contribute to near-term stock volatility from major Bristol shareholders like Wellington Management and Starboard Value, the deal contains favorable terms for shareholders from both companies, Hsieh tells investors in a research note. Further, he believes it is unlikely that a third-party large-cap pharmaceutical company will emerge with an offer for Bristol-Myers before the shareholder meeting. As a result, the analyst expects Celgene shares "will eventually narrow the valuation gap with respect to its fair value," or one share of Bristol plus $50 per share in cash. Hsieh reiterates an Outperform rating on Celgene.
03/01/19
CANT
03/01/19
NO CHANGE
Target $100
CANT
Overweight
Celgene trading well below standalone company value, says Cantor Fitzgerald
Despite concerns about the Bristol-Myers (BMY) buyout deal closing in Q3, Celgene (CELG) at these levels is trading well below its value as a standalone company, Cantor Fitzgerald analyst Alethia Young tells investors in a research note. The analyst sees potential upside long-term for an independent Celgene, but views the deal closing as a positive for shareholders "after a volatile 18 months." She reiterates an Overweight rating on Celgene with a $100 price target. If the deal falls through, Young expects downside of $20 per share back to pre-deal announcement levels. However, she thinks there is more value to Celgene shares over time if the company remains independent.
03/13/19
BARD
03/13/19
NO CHANGE
Target $101
BARD
Outperform
Celgene 'still looks like best option' for Bristol-Myers, says Baird
Baird analyst Brian Skorney notes that on Tuesday, Bristol-Myers (BMY) CEO Giovanni Caforio, speaking at an investor conference, said the company has not had any serious suitors for the company and has not held talks since 2017, when there were no formal offers. In a research note to investors, Skorney says this commentary should help reframe investor expectations as far as what other options Bristol-Myers could explore should the Celgene (CELG) deal fall through, but says Celgene "still looks like the best option." Skorney has an Outperform rating and $101 price target on Celgene.
03/20/19
BMOC
03/20/19
NO CHANGE
Target $62
BMOC
Outperform
Bristol-Myers price target raised to $62 from $59 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Bristol-Myers (BMY) to $62 and kept his Outperform rating, saying its proposed Celgene (CELG) merger is the "right step at the right time." The analyst contends that the company needs to diversify its offerings because of the volatility in immuno-oncology and also boost its long term growth prospects because of the loss of exclusivity for its Eliquis and Opdivo products. Arfaei believes that the combined company will be "meaningfully more diversified and in a better position to fill patent cliffs during 2025-2030" period.
CELG Bought by BMY
$88.34

-1.28 (-1.43%)

03/21/19
BARD
03/21/19
NO CHANGE
Target $250
BARD
Neutral
Biogen 'hate selling' could bring shares to low $200s, says Baird
Baird analyst Brian Skorney lowered his price target for Biogen (BIIB) to $250 from $348 on the failure of aducanumab in Alzheimer's disease. The analyst feels the big question now is, "where is the backstop?" Biogen without the upside potential of Alzheimer's looks a lot like Celgene (CELG) circa 2018, Skorney tells investors in a research note. He thinks investors "will have a hard time seeing anything but risk." The analyst maintains a Neutral rating on Biogen. However, he sees a potential scenario where "hate selling leads to an attractive entry point in the low $200s." The stock in premarket trading s down 27%, or $86.79, to $233.80. Biogen shares "become buyable" in the low $200s, where the company could attract potential suitors, says Skorney.

TODAY'S FREE FLY STORIES

FITB

Fifth Third

$30.24

0.365 (1.22%)

, CSCO

Cisco

$43.83

0.29 (0.67%)

18:37
12/06/19
12/06
18:37
12/06/19
18:37
Hot Stocks
Fifth Third issues statement on temporary network outage »

Fifth Third Bank (FITB)…

FITB

Fifth Third

$30.24

0.365 (1.22%)

CSCO

Cisco

$43.83

0.29 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 08

    Jan

  • 12

    Feb

STML

Stemline

$10.33

0.5 (5.09%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

18:33
12/06/19
12/06
18:33
12/06/19
18:33
Hot Stocks
Stemline names Robert Francomano as Chief Commercial Officer »

Most recently, Francomano…

STML

Stemline

$10.33

0.5 (5.09%)

PFE

Pfizer

$38.29

0.26 (0.68%)

GSK

GlaxoSmithKline

$45.51

0.29 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

GOL

Gol Linhas

$17.39

1.07 (6.56%)

18:31
12/06/19
12/06
18:31
12/06/19
18:31
Hot Stocks
Gol Linhas announces preliminary traffic figures for November »

GOL's domestic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAVB

Navidea

$0.97

0.07 (7.78%)

18:25
12/06/19
12/06
18:25
12/06/19
18:25
Syndicate
Navidea announces $1.9M private placement »

Navidea announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFC

Ellington Financial

$18.22

0.09 (0.50%)

18:23
12/06/19
12/06
18:23
12/06/19
18:23
Hot Stocks
Ellington Financial reports estimated book value per share $18.51 on November 30 »

This estimate includes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOOT

Boot Barn

$41.93

0.81 (1.97%)

18:22
12/06/19
12/06
18:22
12/06/19
18:22
Hot Stocks
Boot Barn CEO: More than 80% of our business is in the store »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERIC

Ericsson

$9.24

0.1 (1.09%)

18:18
12/06/19
12/06
18:18
12/06/19
18:18
Hot Stocks
Ericsson to pay over $1B to settle FCPA case »

Ericsson has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

GLD

SPDR Gold Shares

$137.59

-1.42 (-1.02%)

17:55
12/06/19
12/06
17:55
12/06/19
17:55
Hot Stocks
SPDR Gold Shares holdings fall to 886.23MT from 888.57MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PICO

PICO Holdings

$10.81

0.31 (2.95%)

17:45
12/06/19
12/06
17:45
12/06/19
17:45
Hot Stocks
PICO Holdings sells long-term storage credits for $8.7M in Arizona »

PICO Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QHC

Quorum Health

$0.95

0.0522 (5.81%)

17:31
12/06/19
12/06
17:31
12/06/19
17:31
Hot Stocks
Quorum Health receives NYSE continued listing standard notice »

Quorum Health Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPRT

Support.com

$1.94

0.01 (0.52%)

17:30
12/06/19
12/06
17:30
12/06/19
17:30
Hot Stocks
Breaking Hot Stocks news story on Support.com »

Support.com trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXRX

Baudax Bio

$6.69

0.34 (5.35%)

17:29
12/06/19
12/06
17:29
12/06/19
17:29
Syndicate
Breaking Syndicate news story on Baudax Bio »

Baudax Bio files $125M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

LMT

Lockheed Martin

$387.10

1.175 (0.30%)

17:25
12/06/19
12/06
17:25
12/06/19
17:25
Hot Stocks
Lockheed Martin awarded $153.39M Navy contract modification »

Lockheed Martin was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENV

Envestnet

$71.72

1.27 (1.80%)

17:23
12/06/19
12/06
17:23
12/06/19
17:23
Syndicate
Breaking Syndicate news story on Envestnet »

Envestnet files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$344.79

0.4 (0.12%)

17:20
12/06/19
12/06
17:20
12/06/19
17:20
Hot Stocks
Northrop Grumman awarded $189M Navy contract modification »

Northrop Grumman was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPRT

Support.com

$1.94

0.01 (0.52%)

17:03
12/06/19
12/06
17:03
12/06/19
17:03
Hot Stocks
Support.com announces special distribution of $1.00 per share »

The record date for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPRT

Support.com

$1.94

0.01 (0.52%)

17:01
12/06/19
12/06
17:01
12/06/19
17:01
Hot Stocks
Breaking Hot Stocks news story on Support.com »

Support.com trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RZLT

Rezolute

$0.00

(0.00%)

17:00
12/06/19
12/06
17:00
12/06/19
17:00
Syndicate
Breaking Syndicate news story on Rezolute »

Rezolute files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

16:58
12/06/19
12/06
16:58
12/06/19
16:58
Periodicals
U.S. mulls putting Amazon foreign sites on 'Notorious Markets' list, WSJ says »

The Trump administration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

16:55
12/06/19
12/06
16:55
12/06/19
16:55
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

IMH

IMPAC Mortgage

$5.63

-0.01 (-0.18%)

16:54
12/06/19
12/06
16:54
12/06/19
16:54
Syndicate
Breaking Syndicate news story on IMPAC Mortgage »

IMPAC Mortgage files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALEC

Alector

$19.74

0.33 (1.70%)

16:32
12/06/19
12/06
16:32
12/06/19
16:32
Hot Stocks
Alector reports Phase 1 safety, biomaker data on AL002 »

Alector reported safety…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATAX

America First Multifamily Investors

$7.58

0.125 (1.68%)

16:31
12/06/19
12/06
16:31
12/06/19
16:31
Hot Stocks
America First Multifamily Investors CFO Craig Allen to retire »

On December 2,Craig Allen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
12/06/19
12/06
16:30
12/06/19
16:30
Options
Preliminary option volume of 20.4M today »

Preliminary option volume…

PNM

PNM Resources

$48.77

-0.06 (-0.12%)

16:29
12/06/19
12/06
16:29
12/06/19
16:29
Hot Stocks
PNM Resources raises quarterly dividend 6% to 30.75c per share »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.